Matrix buys back marketing rights for AccuSite:
This article was originally published in Clinica
Executive Summary
Matrix Pharmaceutical has repurchased US and European marketing rights to its AccuSite injectable gel product from Medeva (UK). The company intends to establish a direct sales organisation to market AccuSite and Intradose in the US. In August, Matrix filed for approval in the UK for AccuSite and it plans to submit its New Drug Application with the US FDA for the treatment of genital warts later this month.
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.